ARCUTIS BIOTHERAPEUTICS, INC. Stock Issued During Period, Value, Restricted Stock Award, Gross
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, restricted stock award, gross for the quarter ending 2024-09-30 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, restricted stock award, gross for the quarter ending 2023-03-31 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, restricted stock award, gross for the quarter ending 2022-06-30 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, restricted stock award, gross for the quarter ending 2022-03-31 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, restricted stock award, gross for fiscal 2019 was $8.00K.
| Period end | Stock Issued During Period, Value, Restricted Stock Award, Gross 3 month | Stock Issued During Period, Value, Restricted Stock Award, Gross 12 month |
|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-08-08 | |
| 2019-12-31 | $8.00K 10-K · filed 2022-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |